The proposal presidential hopeful Hillary Clinton unveiled Tuesday to check the "skyrocketing cost of prescription drugs" is a combination of some things old, some things borrowed but nothing new. Read More
Ampio Pharmaceuticals Inc. saw its prospects rise, along with its stock price, after the FDA granted a special protocol assessment (SPA) for the newly launched phase III PIVOT (AP-003-B) trial of co-lead candidate Ampion (aspartyl-alanyl diketopiperazine) to treat pain and inflammation due to osteoarthritis of the knee (OAK). Read More
SHANGHAI – Zai Lab Ltd., located in the well-known Zhangjiang Hi-tech Park, has inked a deal with UCB SA, of Brussels, licensing global rights to its first large molecule asset, set to go into phase I trials in 2016. Read More
DUBLIN – Shares in AB Science SA dipped just 4.7 percent Tuesday on news that it was halting a phase III trial of its tyrosine kinase inhibitor (TKI), masitinib, in rheumatoid arthritis (RA) following a futility analysis, which showed the study's probability of success was below 50 percent. Read More
LONDON – The recently published guidelines for developing biosimilars in China are yet to be tested in practice, but it is evident there are hurdles to be navigated for international pharmas, with the new rules seen as favoring local companies. Read More
Intra-Cellular Therapies Inc., of New York, launched an underwritten public offering of $300 million of its common shares and said it plans to grant underwriters a 30-day option to purchase up to an additional 15 percent of common shares in the offering. Read More
Nanobio Corp., of Ann Arbor, Mich., said its intranasal nanoemulsion (NE) adjuvanted genital herpes vaccine demonstrated efficacy in studies conducted in both prophylactic and therapeutic guinea pig models. Read More
Bioblast Pharma Ltd., of Tel Aviv, Israel, appointed Paul Firuta chief commercial officer, and said it has established its U.S. headquarters in New Haven, Conn. Read More
Galapagos NV, of Mechelen, Belgium, said it expects to file plans for an exploratory phase II study of its autotaxin inhibitor, GLPG-1690, in idiopathic pulmonary fibrosis before year-end after finding encouragement in preclinical and phase I results that the company is presenting at the European Respiratory Society Annual Meeting in Amsterdam, the Netherlands. Read More
